UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000030574
Receipt number R000034342
Scientific Title Evaluation of pre-medication of olanzapine for post-operative nausea and vomiting in the gynecology surgical patients: a randomized placebo-controlled trial
Date of disclosure of the study information 2018/01/01
Last modified on 2019/05/28 20:24:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of pre-medication of olanzapine for
post-operative nausea and vomiting in the gynecology surgical patients: a randomized placebo-controlled trial

Acronym

Evaluation of pre-medication of olanzapine for post-operative nausea and vomiting in the gynecology surgical patients: a randomized placebo-controlled trial

Scientific Title

Evaluation of pre-medication of olanzapine for
post-operative nausea and vomiting in the gynecology surgical patients: a randomized placebo-controlled trial

Scientific Title:Acronym

Evaluation of pre-medication of olanzapine for post-operative nausea and vomiting in the gynecology surgical patients: a randomized placebo-controlled trial

Region

Japan


Condition

Condition

Gynecological surgery patiets

Classification by specialty

Anesthesiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to develop the prevention of postoperative nausea and vomiting (PONV). We compare the incidence of PONV in high risk patients using dexamethasone or olanzapine. And we will make clear the efficacy of olanzapine for PONV.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Phase III


Assessment

Primary outcomes

The incidence of not PONV after 24 hours after
operation

Key secondary outcomes

The incidence of PONV every hour
The incidence of no nausea and no vomiting every hour
The severity of nausea every hour
The frequency of using anti-emetic agents every hour


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Medicine

Interventions/Control_1

Administration of 5mg of olanzapine before 1 hour of admission of operating room

Interventions/Control_2

Administration of placebo before 1 hour of admission of operating room

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Female

Key inclusion criteria

gynecologic surgical patients
no smoking patients

Key exclusion criteria

the contraindication

Target sample size

106


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Tomoyuki Kawamata

Organization

Wakayama Medical University

Division name

Department of Anesthesiology

Zip code


Address

811-1 Kimiidera, Wakayama City

TEL

073-441-0610

Email

kawamata@wakayama-med.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Toshiyuki Kuriyama

Organization

Wakayama Medical University

Division name

Department of Anesthesiology

Zip code


Address

811-1 Kimiidera, Wakayama City

TEL

073-441-0610

Homepage URL

http://www.wakayama-masui.jp

Email

kuriyama@xa2.so-net.ne.jp


Sponsor or person

Institute

Department of Anesthesiology, Wakayama Medical University

Institute

Department

Personal name



Funding Source

Organization

Wakayama Medical University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

2153

Org. issuing International ID_1

Wakayama Medical University

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

和歌山県立医科大学附属病院


Other administrative information

Date of disclosure of the study information

2018 Year 01 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2017 Year 11 Month 09 Day

Date of IRB

2017 Year 11 Month 09 Day

Anticipated trial start date

2018 Year 01 Month 04 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry

2019 Year 03 Month 31 Day

Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2017 Year 12 Month 26 Day

Last modified on

2019 Year 05 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000034342


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name